Study of Rivaroxaban for Cerebral Venous Thrombosis: A Randomized Controlled Feasibility Trial Comparing Anticoagulation With Rivaroxaban to Standard-of-Care in Symptomatic Cerebral Venous Thrombosis
Thalia S. Field,Vanessa Dizonno,Mohammed A. Almekhlafi,Fouzi Bala,Ibrahim Alhabli,Hubert Wong,Monica Norena,Maria Karina Villaluna,Princess King-Azote,Namali Ratnaweera,Steven Mancini,Stephen C. Van Gaal,Laura K. Wilson,Brett R. Graham,Luciano A. Sposato,Dylan Blacquiere,Brian M. Dewar,Mark I. Boulos,Brian H. Buck,Celine Odier,Kanjana S. Perera,Aleksandra Pikula,Aleksander Tkach,George Medvedev,Carolyn Canfield,W. Ben Mortenson,Janel O. Nadeau,Sohaila Alshimemeri,Oscar R. Benavente,Andrew M. Demchuk,Dar Dowlatshahi,Sylvain Lanthier,Agnes Y.Y. Lee,Jennifer Mandzia,Deepa Suryanarayan,Jeffrey I. Weitz,Michael D. Hill,Michael Hill,Karina Villaluna Murray,Andrea Jones,Lauren Matsubara,Zoe O’Neill,Sarah Park,Michelle Yuan,Marina Saluzzi,Ashley Dueck,K. Ingrid McKibben,Qiao Zhang,Oscar Benavente (chair),Ken Butcher (chair),Cheryl Bushnell,Diana Aguiar de Sousa,Michael Hill,Oscar Benavente,Dr Laura Wilson,Oscar Benavente,Mar Lloret,Hsien Lee Lau,Genoveva Maclean,Sharanpal Mann,Colleen Murphy,Jonathan Smith,Philip Teal,Ming Yin (Dominic) Tse,Samuel Yip,VIshaya Naidoo,Jaskiran Brar,Shuo Chen,Myles Horton,Michael Hill,Supriya Save,Shorog Althubait,Chrysi Bogiatzi,Matthew Boyko,Surbhi Chatuverdi,Shelagh Coutts,Aravind Ganesh,Kimia Ghavami,Emme Harrison,Sherry Hu,Anitha Jambula,Raed Joundi,Carol Kenney,Gary Klein,Katie Lin,Salman Mansoor,Martha Marko,Karla Ryckborst,Kayla Sage,Nishita Singh,Ming Yin (Dominic) Tse,Ankur Wadhwa,Sanchea Wasiliw,Brett Graham,Shrijal Bhavsar,Kala Bold,Sharleen Maley,Lilian Urroz,Kaitlyn Foster,Emily Junk,Scott Corley,Aaron Gardner,Jennifer McMullen,Ruth Whelan,Whitney Duff,Cassandra Tyson,Regan Cooley,Gary Hunter,Fergall Magee,Sanchea Wasyliw,Meribeth-Ann (Beth) Beauchamp,Lindsay Lambourn,Diana Ayan,Aleksander Khaw,Lauren Mai,Maria Bres Bullrich,Sebastian Fridman,Zeinab Daham,Robert Fahad,Michel Shamy,Grant Stotts,Idris Fatadawala,Kaitlyn Lopes,Alisia Southwell,Vinaya Bhandari,Tess Fitzpatrick,David Gladstone,Julia Hopyan,Maneesha Kamra,Houman Khosravani,Anne-Marie Liddy,Zhongyu Liu,Najla Popel,Keith Sivakumar,Richard Swartz,Amy Yu,Paige Fairall,Farhat Ahmed,Juline Jabs,Leah White,Lori Piquette,Rekha Shepherd,Noman Ishaque,Céline Odier,Nandy-Shelwine Simon,Marlene Lapierre,Olena Bereznyakova,Casey Boudreau Caporuscio,Francois Cauchon,Valerie Côté,Nicole Denault,Yan Desciantre,Lyne Gauthier,Laura Gioia,Grégory Jaquin,Nadia Jadil,Sothun Lim,Alexandra Poppe,Caludia Rodriguez,Marie-Christine Rodriguez,Christian Stapf,Cheyenne Vandervelde,Kuan Huei (Kelvin) Ng,Wes Oczkowski,Diane Lourenco,Cathay Moreau,Amber Jolie,Vinai Bhagraith,Aristeidis Katsanos,Danielle de Sa Boasquevisque,Kanchana Ratnayake,Marie McLelland,Coleen Adderly,Elsadig Elamin,Camille Galloway,Michelle Smith,Tess Topor,Shobha Singh,William To,Farhana Akthar,Leanne Casaubon,Anne Cayley,Lisa Crelling,Martin Del Campo,Mingyang Gao,Cresti Hanna,Muhammad Khalid,Nga Pham,Joanna Schaafsma,Frank Silver,TIm Stewart,Patricia Tiopanas,Rely Wigner,Janice Williams
DOI: https://doi.org/10.1161/STROKEAHA.123.044113
IF: 10.17
2023-09-09
Stroke
Abstract:Stroke, Ahead of Print. Background:Emerging data suggest that direct oral anticoagulants may be a suitable choice for anticoagulation for cerebral venous thrombosis (CVT). However, conducting high-quality trials in CVT is challenging as it is a rare disease with low rates of adverse outcomes such as major bleeding and functional dependence. To facilitate the design of future CVT trials, SECRET (Study of Rivaroxaban for Cerebral Venous Thrombosis) assessed (1) the feasibility of recruitment, (2) the safety of rivaroxaban compared with standard-of-care anticoagulation, and (3) patient-centered functional outcomes.Methods:This was a phase II, prospective, open-label blinded-end point 1:1 randomized trial conducted at 12 Canadian centers. Participants were aged ≥18 years, within 14 days of a new diagnosis of symptomatic CVT, and suitable for oral anticoagulation; they were randomized to receive rivaroxaban 20 mg daily, or standard-of-care anticoagulation (warfarin, target international normalized ratio, 2.0–3.0, or low-molecular-weight heparin) for 180 days, with optional extension up to 365 days. Primary outcomes were annual rate of recruitment (feasibility); and a composite of symptomatic intracranial hemorrhage, major extracranial hemorrhage, or mortality at 180 days (safety). Secondary outcomes included recurrent venous thromboembolism, recanalization, clinically relevant nonmajor bleeding, and functional and patient-reported outcomes (modified Rankin Scale, quality of life, headache, mood, fatigue, and cognition) at days 180 and 365.Results:Fifty-five participants were randomized. The rate of recruitment was 21.3 participants/year; 57% of eligible candidates consented. Median age was 48.0 years (interquartile range, 38.5–73.2); 66% were female. There was 1 primary event (symptomatic intracranial hemorrhage), 2 clinically relevant nonmajor bleeding events, and 1 recurrent CVT by day 180, all in the rivaroxaban group. All participants in both arms had at least partial recanalization by day 180. At enrollment, both groups on average reported reduced quality of life, low mood, fatigue, and headache with impaired cognitive performance. All metrics improved markedly by day 180.Conclusions:Recruitment targets were reached, but many eligible participants declined randomization. There were numerically more bleeding events in patients taking rivaroxaban compared with control, but rates of bleeding and recurrent venous thromboembolism were low overall and in keeping with previous studies. Participants had symptoms affecting their well-being at enrollment but improved over time.REGISTRATION:URL:https://www.clinicaltrials.gov; Unique identifier: NCT03178864.
peripheral vascular disease,clinical neurology